VTR

SEC Filing Summary: Vencor, Inc. (Form 10-K)

Business Context and Reporting Period

Company: Vencor, Inc. (Note: The filing text identifies the registrant as Vencor, Inc., despite the metadata reference to Ventas, Inc.)
Period: Fiscal year ended December 31, 1996.
Business Overview: Vencor is a major provider of healthcare services for the elderly, operating an integrated network of long-term acute care hospitals, skilled nursing centers, contract healthcare services (Vencare), and assisted/independent living communities (Atria). As of December 31, 1996, the company operated 38 hospitals (3,325 beds), 313 nursing centers (39,619 beds), and 21 Atria communities (2,942 units). The company completed the Hillhaven Merger in 1995 and the IPO of Atria in 1996.

Key Financial Metrics

Revenue Mix (1996): Nursing centers (62%), Hospitals (21%), Vencare contract services (15%), Atria (2%).

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 10.9% to $2.58 billion, driven by a 20.8% increase in hospital revenues (due to volume growth) and a 26.1% increase in Vencare contract services.
• Non-Recurring Charges: 1996 results were significantly impacted by $125.2 million in pretax non-recurring charges ($79.9 million net of tax). These included a $65.3 million charge for the planned sale of 34 nursing centers and a $39.6 million charge for integrating pharmacy operations into Vencare.
• Profitability: Despite the charges, income from operations increased 25% to $127.9 million on an adjusted basis (excluding non-recurring items) compared to the prior year.
• Liquidity: Working capital improved by $80.4 million to $320.1 million. Cash provided by operations increased by $69.9 million year-over-year.
• Debt Reduction: Long-term debt decreased by $67.6 million due to repayments and refinancing activities.

Guidance, Outlook, and Risks

• Strategic Outlook: Management plans to spend approximately $200 million over two years to improve nursing center facilities and expand services for higher-acuity patients. Capital expenditures for 1997 are projected at $200–$250 million (excluding acquisitions).
• Recent Acquisitions: On March 21, 1997, the company completed the acquisition of TheraTx, Inc. for $17.10 per share, adding subacute rehabilitation and respiratory therapy services. A new $1.6 billion credit facility was established to support this.
• Key Risks:
  • Regulatory & Reimbursement: Significant reliance on Medicare (31% of revenue) and Medicaid (31% of revenue). Changes in reimbursement rates, cost-containment measures, or regulatory compliance (e.g., OBRA, Stark Provisions) could materially impact results.
  • Legislative: Potential healthcare reform or federal budget balancing efforts could reduce government spending.
  • Competition: Intense competition for private pay patients and managed care contracts.
• Contingencies: The company is subject to various lawsuits and claims, though management believes these are covered by insurance or will not have a material adverse effect.

Investor Verification Checklist

• Non-Recurring Items: Verify the impact of the $125.2 million restructuring charge on the true operating performance and future cash flows.
• Accounts Receivable: Review the growth in outstanding days of revenue in accounts receivable, which management cites as an adverse factor for 1997 cash flows.
• Debt Covenants: Confirm continued compliance with financial ratios required by the $1.6 billion credit facility and the Atria Credit Facility.
• TheraTx Integration: Assess the financial impact and integration progress of the March 1997 TheraTx acquisition.
• Medicaid/Medicare Audits: Monitor potential retroactive adjustments from government audits of cost reports, which could affect future revenue recognition.